Free Trial
Brad Canino

Brad Canino Analyst Performance

Biotechnology Equity Research Analyst at Guggenheim

Brad Canino is a stock analyst at Guggenheim in the medical sector, covering 10 publicly traded companies. Over the past year, Brad Canino has issued 15 stock ratings, including buy and hold recommendations. While full access to Brad Canino's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Brad Canino's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
15 Last 0 Years
Buy Recommendations
93.33% 14 Buy Ratings
Companies Covered
10 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy93.3%14 ratings
Hold6.7%1 ratings
Sell0.0%0 ratings

Out of 15 total stock ratings issued by Brad Canino at Guggenheim, the majority (93.3%) have been Buy recommendations, followed by 6.7% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
10 companies

Brad Canino, an analyst at Guggenheim, currently covers 10 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
10 companies
100.0%

Brad Canino of Guggenheim specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
7 companies
70.0%
MED - DRUGS
3 companies
30.0%

Brad Canino's Ratings History at Guggenheim

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Celcuity, Inc. stock logo
CELC
Celcuity
9/22/2025Initiated Coverage$51.88Buy
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
9/4/2025Initiated Coverage$8.43Neutral
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
9/4/2025Initiated Coverage$10.60$18.00Buy
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
9/4/2025Initiated Coverage$4.02$15.00Buy
Nuvalent, Inc. stock logo
NUVL
Nuvalent
9/4/2025Initiated Coverage$78.82$122.00Buy
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
9/3/2025Initiated Coverage$23.52$40.00Buy
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
9/3/2025Initiated Coverage$1.47$5.00Buy
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
9/3/2025Initiated Coverage$23.04$72.00Buy
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
9/3/2025Initiated Coverage$2.56$8.00Buy
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
9/3/2025Initiated Coverage$2.88$8.00Buy
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
9/3/2025Initiated Coverage$2.94$8.00Buy
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
9/3/2025Initiated Coverage$23.98$72.00Buy
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
9/3/2025Initiated Coverage$1.91$5.00Buy
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
9/3/2025Initiated Coverage$2.71$8.00Buy
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
9/3/2025Initiated Coverage$19.44$40.00Buy